Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Sarcoma 39Lymphoma 38Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 22Osteosarcoma 15Burkitt Lymphoma 14Hodgkin Disease 13Testicular Neoplasms 11Recurrence 9Leukemia 9Neuroectodermal Tumors, Primitive, Peripheral 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Teratoma 7Ovarian Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Germ Cell Tumor 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Carcinoma, Embryonal 6Breast Neoplasms 6Rhabdomyosarcoma 5Lymphoma, Large-Cell, Anaplastic 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms, Germ Cell and Embryonal 4Lymphoma, B-Cell 4

Interventions

Cyclophosphamide 5Rituximab 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2blinatumomab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2pembrolizumab 1Vorinostat 1CLR1404 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoproliferative Disorders × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡